{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Unable to retrieve a sufficient amount of archived samples to perform an analysis therefore the study was not able to verify the FLT3-ITD mutation status","groups":[{"description":"Patients received standard of care in the post stem cell transplant (SCT) setting in addition to Midostaurin 50mg twice a day for 12 months (cycles).","id":"OG000","title":"Standard of Care With Midostaurin"},{"description":"Patients received standard of care alone in the post SCT setting","id":"OG001","title":"Standard of Care"}],"populationDescription":"Insufficient amount of samples to perform analysis","reportingStatus":"POSTED","timeFrame":"up to 24 months from date of transplannt or at study completion","title":"FLT3-ITD Mutation Status Centrally in Archived Material From Diagnosis (if Available) Including Mutant:Wild Type Ratio.","type":"SECONDARY"}